DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for epidermolysis bullosa dystrophica — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEpidermolysis bullosa dystrophica maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for epidermolysis bullosa dystrophica is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The dystrophic forms of epidermolysis bullosa (DEB) are caused by mutations in the COL7A1 gene, which encodes type VII collagen, the main component of anchoring fibrils at the dermal-epidermal junction. In a molecular diagnostics laboratory that analysed over 1000 families with epidermolysis bullosa, including 332 with DEB, 355 mutant alleles out of an anticipated 438 (81.1%) were identified. Among these, 242 distinct mutations were found, 138 of which were novel. No evidence of mutations in any other gene was obtained. Examination of this mutation database suggested phenotype-genotype correlations that contributed to improved subclassification of DEB with prognostic implications, and the mutation information formed the basis for genetic counselling and prenatal diagnosis.
By 2010, inherited epidermolysis bullosa was known to be caused by mutations in at least 14 genes, leading to a broad spectrum of entities with different risks for extracutaneous complications and premature death. Detailed evidence-based data on these risks had become available for each major subtype. Studies were underway to explain the biological aggressiveness of squamous cell carcinomas arising in epidermolysis bullosa skin. Cell and animal models had been refined and used to test the feasibility of gene replacement therapy, stem cell transplantation, and treatment with injected allogeneic fibroblasts or recombinant type VII collagen. Clinical trials pursuing each of these approaches in humans were being initiated.
In a single family report of three cases of dystrophic epidermolysis bullosa across three generations comprising 18 individuals, two cases were female and one male. The index case was of the vegetans type, while the other two were the usual dystrophic type. The authors emphasised autosomal recessive transmission and highlighted unusual clinical and histological features in the latter two cases. They also stated a therapeutic role for vitamin E at a dose of 300 mg per day in management, but this claim comes from a small, uncontrolled family report, not a randomised trial.
What is still missing are large, controlled clinical trials for any proposed treatment, including vitamin E, gene therapy, stem cell transplantation, and fibroblast or collagen injections. The genetic basis is well characterised, but translating that knowledge into reliable, reproducible treatments that alter the course of the disease in most patients has not been achieved. Patient stratification by specific COL7A1 mutation type may be necessary, and funding for adequately powered trials remains a barrier.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Medical Genetics · 2006 · 280 citations · open access
Epidermolysis bullosa. II. Type VII collagen mutations and phenotype–genotype correlations in the dystrophic subtypes
AbstractBACKGROUND: The dystrophic forms of epidermolysis bullosa (DEB), a group of heritable blistering disorders, show considerable phenotypic variability, and both autosomal dominant and autosomal recessive inheritance can be recognised. DEB is derived from mutations in the type VII collagen gene (COL7A1), encoding a large collagenous protein that is the predominant, if not exclusive, component of the anchoring fibrils at the dermal-epidermal junction. METHODS: The Dystrophic Epidermolysis Bullosa Research Association Molecular Diagnostics Laboratory (Philadelphia, Pennsylvania, USA), established in 1996, has analysed more than 1000 families with different forms of epidermolysis bullosa, among them 332 families with DEB. DNA specimens were subjected to mutation analysis by polymerase chain reaction (PCR) amplification of all 118 exons and flanking intronic sequences of COL7A1, followed either by heteroduplex scanning and sequencing of the PCR products demonstrating heteroduplexes or by direct nucleotide sequencing. RESULTS: 355 mutant alleles out of the anticipated 438 (81.1%) were disclosed. Among these mutations, a total of 242 mutations were distinct and 138 were novel, previously unreported mutations. No evidence of mutations in any other gene was obtained. DISCUSSION: Examination of the mutation database suggested phenotype-genotype correlations, contributing to the improved subclassification of DEB with prognostic implications. The mutation information also forms the basis for accurate genetic counselling and prenatal diagnosis in families at risk for recurrence.
Current Opinion in Pediatrics · 2010 · 54 citations
Inherited epidermolysis bullosa: recent basic and clinical advances
AbstractPURPOSE OF REVIEW: This review highlights key findings, both clinical and basic, that have been published in the field of inherited epidermolysis bullosa within the past few years. RECENT FINDINGS: New epidermolysis bullosa phenotypes, genotypes and modes of transmission have been identified, resulting in a revised classification system. Detailed evidence-based data are now available on the risk of extracutaneous complications in each of the major epidermolysis bullosa subtypes. Studies are now underway to try to better explain the biological aggressiveness of squamous cell carcinomas arising in epidermolysis bullosa skin. Cell and animal models have been refined and used to ascertain the feasibility of gene replacement therapy, stem cell transplantation, and treatment with injected allogeneic fibroblasts or recombinant type VII collagen. As a result, clinical trials are now being pursued to test each of these in humans. SUMMARY: Epidermolysis bullosa is caused by mutations in at least 14 genes, leading to a broad spectrum of entities, each of which has its own relative risk for the development of specific extracutaneous complications and/or premature death. Intensive research, both basic and clinical, is bringing us closer to more effective treatments and possibly even a cure.
AbstractThree cases of the dystrophic type of epidermolysis bullosa in three generations comprising 18 individuals are described. Two of the three cases were females and the other male. The index case was of the vegetans type, while the other two cases were the usual dystrophic type. The unusual clinical and histological features in the latter cases are highlighted. The autosomal recessive transmission of the disease is brought out. The therapeutic role of vitamin E in dosage of 300 mg per day in the management of these cases is emphasized.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
